• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery

    3/19/25 9:15:00 AM ET
    $ILMN
    Medical Specialities
    Health Care
    Get the next $ILMN alert in real time by email

    Creates one of the largest, most comprehensive clinical genomic datasets of its kind; multiomic data to be added in next phase of program      

    AGD members are using the population-level insights to uncover novel drug targets

    SAN DIEGO, March 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ:ILMN) and Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced that 250,000 whole genomes have been sequenced for the Alliance for Genomic Discovery (AGD) initiative. Insights from the AGD database are being leveraged to accelerate drug target discovery, therapeutic research and clinical development.

    Illumina and NashBio announce that the Alliance for Genomic Discovery – a consortium of biotech and biopharma organizations – has completed its initial goal of sequencing 250,000 whole genomes in just two years, creating one of the world's largest and most comprehensive clinical genomic datasets of its kind.

    "AGD is delivering on its promise of unlocking new discoveries, and we're eager to build on this success with the addition of multiomic measurements to drive advances in therapeutic development," said Todd Christian, senior vice president of services, arrays, and genomic access at Illumina. "The rapid achievement of this major milestone demonstrates the value of our strategic collaborations across the ecosystem to advance unprecedented progress in biologic and therapeutic discovery." 

    An unparalleled R&D resource    

    The resulting AGD dataset is being made available to the alliance's eight biopharma members using Illumina Connected Analytics as a shared research tool and data platform. De-identified DNA samples were provided by NashBio from VUMC's BioVU® biobank, and sequenced by deCODE genetics, a subsidiary of Amgen, using Illumina's complete, end-to-end sequencing workflow including the DRAGEN analysis pipeline, and integrated with de-identified longitudinal clinical phenotype data derived from VUMC's electronic health record data.      

    "The AGD dataset is unique for its diversity and depth and has already proven its value by empowering us to make important discoveries we would not have made without it," said Kári Stefánsson, CEO of deCODE genetics.

    A study published in Nature in 2024 indicates that drugs in development with a genetic basis are 2.6 times more likely to succeed than those without. This supports the significant impact of genetic evidence in the field of drug discovery.

    The data generated through AGD will provide a dynamic research platform for years to come and has already yielded initial novel target discoveries and validations by biopharma company members across autoimmune, liver fibrotic, and metabolic diseases. The diversity of data types, demographics, ancestries, and diseases represented in the dataset makes it a valuable resource for life sciences exploration. 

    The next phase of the Alliance for Genomic Discovery will double down on multiomics    

    In the next phase of AGD, its members plan to further expand the breadth, depth, and diversity of the dataset by adding multiomic layers.  

    "We have received extensive AGD member and broader customer interest," said Leeland Ekstrom, PhD, chief executive officer of NashBio. "Based on this extensive market interest, we're exploring proteomics and other omics modalities to further elucidate the underlying mechanisms of disease and enable discovery of promising targets for pharmacological intervention. The whole genomes of 'AGD 1.0' are only the start."

    As Illumina expands its portfolio of multiomic capabilities, the Alliance for Genomic Discovery anticipates that it will use these technologies to further enrich the dataset and drive deeper biological insights. Illumina recently unveiled a road map of innovations that will establish the industry's largest portfolio of omics solutions and sequencing applications, spanning genomics, spatial transcriptomics, single-cell analysis, CRISPR technologies, epigenetics, and data analytics software.

    AGD began sequencing to develop its clinical genomic database in January 2023, making it one of the fastest large-scale genomics projects to date. Originally, sequencing was projected to complete later in 2025. Similar programs have required three to five years to complete 100,000 whole genomes. The speed of this effort reflects the collaborative impact of AGD and its participating life sciences organizations.

    About the Alliance for Genomic Discovery

    Launched in 2022 by Illumina and NashBio, the Alliance for Genomic Discovery is a multiyear endeavor aiming to accelerate development of therapeutics through large-scale genomics and the establishment of a preeminent clinical genomic resource. Member companies AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Merck, and Novo Nordisk leverage the data resource to identify disease associations and targets for intervention.

    To develop the dataset, Illumina next-generation sequencing solutions were used to analyze whole-genome data derived from Vanderbilt University Medical Center's BioVU®, an extensive, high-quality biobank of more than 250,000 de-identified human DNA samples and associated longitudinal, structured, and de-identified clinical data. One of the main objectives of the alliance is to help narrow the gap in the diversity of genomic data and ultimately work toward a more equitable representation of ancestries in genetic research. Learn more at nashbio.com/agd.

    Use of forward-looking statements

    This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

    About Illumina

    Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

    About NashBio

    Nashville Biosciences LLC (NashBio), a wholly owned, for-profit subsidiary of Vanderbilt University Medical Center (VUMC), was created to make complex healthcare data easy to use for a wide range of life science research and development applications. Leveraging Vanderbilt University innovation, NashBio harnesses extensive real-world genomics and other longitudinal multi-modal datasets, along with powerful bioinformatics tools, to build and deliver a wide range of data products and services. NashBio works with clients in biotech, pharma, diagnostics, medical devices, and other life sciences domains to support their most critical use cases. We believe smarter data enables better outcomes for our clients and ultimately for patients. For more information, please visit NashBio.com, connect with us on LinkedIn or follow us on X at @NashvilleBio.

    Contacts

    Investors:

    Salli Schwartz

    858-291-6421

    [email protected]

    Media:

    Christine Douglass

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/alliance-for-genomic-discovery-completes-250-000-whole-genomes-to-accelerate-drug-discovery-302405464.html

    SOURCE Illumina, Inc.

    Get the next $ILMN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ILMN

    DatePrice TargetRatingAnalyst
    3/4/2025$130.00 → $90.00Neutral
    Citigroup
    2/28/2025$100.00Buy → Hold
    HSBC Securities
    2/10/2025$130.00 → $100.00Equal Weight → Underweight
    Barclays
    2/7/2025$177.00 → $140.00Buy → Hold
    TD Cowen
    12/11/2024$190.00 → $165.00Buy → Neutral
    Citigroup
    11/12/2024$156.00Equal-Weight
    Morgan Stanley
    10/17/2024$180.00Hold → Buy
    HSBC Securities
    8/28/2024Hold → Buy
    Argus
    More analyst ratings

    $ILMN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Illumina Reports Financial Results for First Quarter of Fiscal Year 2025

      Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis)GAAP operating margin of 15.8% and non-GAAP operating margin of 20.4% for Q1 2025GAAP diluted EPS of $0.82 and non-GAAP diluted EPS of $0.97 for Q1 2025Cash provided by operations of $240 million and free cash flow of $208 million for Q1 2025For fiscal year 2025, we expect:Core Illumina revenue to decline between (1%) and (3%) on a constant currency basis year over year, down from low single digit growth previouslyRevenue outside of the Greater China region expected to grow between 0% and 2% in 2025 on a constant currency basis year over year and includes our estimate reflecting change

      5/8/25 4:13:00 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development

      First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies Dataset will advance development of GLP-1 therapies in new indications and accelerate discovery of novel drug targets in patients who are unresponsive to therapies SAN DIEGO, May 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), and Ovation.io, Inc., an organization dedicated to building best-in-class multiomics datasets, today announced the development of the largest commercially available clinical multiomic dataset from 25,000 patients treated with glucagon-like peptide-1 (GLP-1) receptor agonist therapies. The dataset will be made available to the pharma community

      5/1/25 9:15:00 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation

      Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO, April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ:ILMN) and Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. The collaboration will combine leading Illumina AI technologies with Tempus's comprehensive multimodal data platform to train genomic algorithms and ultimately accelerate clinical adoption of molecular testing for patients.

      4/15/25 9:15:00 AM ET
      $ILMN
      $TEM
      Medical Specialities
      Health Care
      Computer Software: Programming Data Processing
      Technology

    $ILMN
    Financials

    Live finance-specific insights

    See more
    • Illumina Reports Financial Results for First Quarter of Fiscal Year 2025

      Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis)GAAP operating margin of 15.8% and non-GAAP operating margin of 20.4% for Q1 2025GAAP diluted EPS of $0.82 and non-GAAP diluted EPS of $0.97 for Q1 2025Cash provided by operations of $240 million and free cash flow of $208 million for Q1 2025For fiscal year 2025, we expect:Core Illumina revenue to decline between (1%) and (3%) on a constant currency basis year over year, down from low single digit growth previouslyRevenue outside of the Greater China region expected to grow between 0% and 2% in 2025 on a constant currency basis year over year and includes our estimate reflecting change

      5/8/25 4:13:00 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025

      SAN DIEGO, April 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2025 following the close of market on Thursday, May 8, 2025.  On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.  Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, May 8, 2025. Interested parties may access the live webcast via the Investor Info section of Illumina's w

      4/10/25 4:05:00 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2024

      Core Illumina revenue of $1.1 billion for Q4 2024, up 1% from Q4 2023 on both a reported and constant currency basis; revenue of $4.3 billion for fiscal year 2024, down 2% from fiscal year 2023 on both a reported and constant currency basisCore Illumina GAAP operating margin of 15.8% and non-GAAP operating margin of 19.7% for Q4 2024; GAAP operating margin of 34.0% and non-GAAP operating margin of 21.3% for fiscal year 2024Core Illumina GAAP diluted earnings per share (EPS) of $0.73 and non-GAAP diluted EPS of $0.95 for Q4 2024; GAAP diluted EPS of $5.61 and non-GAAP diluted EPS of $4.16 for fiscal year 2024Core Illumina cash provided by operations of $1.2 billion and free cash flow of $1.1

      2/6/25 4:05:00 PM ET
      $ILMN
      Medical Specialities
      Health Care

    $ILMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Thaysen Jacob bought $991,672 worth of shares (7,330 units at $135.29), increasing direct ownership by 97% to 14,861 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      2/26/24 8:57:29 AM ET
      $ILMN
      Medical Specialities
      Health Care

    $ILMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Strategy/Corp Development Wedel Christensen Jakob covered exercise/tax liability with 384 shares and returned $42,388 worth of shares to the company (549 units at $77.21), decreasing direct ownership by 7% to 11,808 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      5/7/25 4:09:16 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • SVP, Chief Information Officer Rollins Carissa covered exercise/tax liability with 113 shares, decreasing direct ownership by 0.61% to 18,447 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      4/8/25 4:06:14 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Director Meister Keith A. was granted 625 shares (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      4/1/25 4:53:53 PM ET
      $ILMN
      Medical Specialities
      Health Care

    $ILMN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup reiterated coverage on Illumina with a new price target

      Citigroup reiterated coverage of Illumina with a rating of Neutral and set a new price target of $90.00 from $130.00 previously

      3/4/25 8:10:42 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • Illumina downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded Illumina from Buy to Hold and set a new price target of $100.00

      2/28/25 9:03:13 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • Illumina downgraded by Barclays with a new price target

      Barclays downgraded Illumina from Equal Weight to Underweight and set a new price target of $100.00 from $130.00 previously

      2/10/25 6:59:21 AM ET
      $ILMN
      Medical Specialities
      Health Care

    $ILMN
    Leadership Updates

    Live Leadership Updates

    See more
    • Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors

      Stephen MacMillan to retire from the Board SAN DIEGO, March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today announced changes to its Board of Directors. Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board. Dr. Gottlieb has served on the Board of Directors since 2020. Additionally, Keith Meister, founder, Managing Partner, and Chief Investment Officer of Corvex Management, will join the Board of Directors on March 28, 2025. Stephen MacMillan, Chairman, President, and CEO of Hologic, who joined the Illumina Board in June 2023, has decided to retire from the board in preparation for the company

      3/25/25 9:00:00 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S

      6/7/24 6:09:00 PM ET
      $ADTN
      $ALTR
      $ATNI
      $BMRN
      Telecommunications Equipment
      Utilities
      Computer Software: Prepackaged Software
      Technology
    • Illumina appoints Everett Cunningham Chief Commercial Officer

      Cunningham previously served as CCO for Exact Sciences and brings more than 20 years of commercial leadership across healthcare tech, life sciences, and pharma  SAN DIEGO, June 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the appointment of Everett Cunningham as Chief Commercial Officer (CCO), effective June 10.    Cunningham will be responsible for building, guiding, and managing the company's global commercial organization. He brings extensive commercial experience across the healthcare

      6/3/24 7:11:00 AM ET
      $ILMN
      Medical Specialities
      Health Care

    $ILMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Illumina Inc.

      SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

      12/6/24 10:11:24 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Illumina Inc.

      SC 13G - ILLUMINA, INC. (0001110803) (Subject)

      12/5/24 7:27:01 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Illumina Inc.

      SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

      11/12/24 3:59:44 PM ET
      $ILMN
      Medical Specialities
      Health Care

    $ILMN
    SEC Filings

    See more
    • Illumina Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ILLUMINA, INC. (0001110803) (Filer)

      5/8/25 4:24:10 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • SEC Form DEFR14A filed by Illumina Inc.

      DEFR14A - ILLUMINA, INC. (0001110803) (Filer)

      4/16/25 4:18:52 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • SEC Form DEFA14A filed by Illumina Inc.

      DEFA14A - ILLUMINA, INC. (0001110803) (Filer)

      4/9/25 4:51:02 PM ET
      $ILMN
      Medical Specialities
      Health Care